Targeted Drug/Gene/Photodynamic Therapy via a Stimuli‐Responsive Dendritic‐Polymer‐Based Nanococktail for Treatment of EGFR‐TKI‐Resistant Non‐Small‐Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Materials"
DOI: 10.1002/adma.202201516
Abstract: Yes‐associated protein (YAP) has been identified as a key driver for epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) resistance. Inhibition of YAP expression could be a potential therapeutic option for treating non‐small‐cell lung cancer (NSCLC).… read more here.
Keywords: cell; egfr tki; therapy; dendritic polymer ... See more keywords
Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3734
Abstract: Despite the progress of advanced target therapeutic agents and immune checkpoint inhibitors, EGFR‐TKI resistance is still one of the biggest obstacles in treating lung cancer. Clinical studies with autophagy inhibitors are actively underway to overcome… read more here.
Keywords: egfr tki; tki; targeting yap; p62 signaling ... See more keywords
Inequalities in survival and care across social determinants of health in a cohort of advanced lung cancer patients in Quebec (Canada): A high-resolution population-level analysis.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5897
Abstract: BACKGROUND Advanced lung cancer patients exposed to breakthrough therapies like EGFR tyrosine kinase inhibitors (EGFR-TKI) may experience social inequalities in survival, partly from differences in care. This study examined survival by neighborhood-level socioeconomic and sociodemographic… read more here.
Keywords: lung cancer; egfr tki; advanced lung; cancer patients ... See more keywords
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Sign Up to like & getrecommendations! Published in 2019 at "Targeted Oncology"
DOI: 10.1007/s11523-019-00657-1
Abstract: The first (1G) and second (2G) generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show differential inhibitory capacities towards EGFR T790M-mutated non-small-cell lung cancer (NSCLC) cells. To assess the ratio of the… read more here.
Keywords: egfr mutated; egfr; acquired t790m; efficacy osimertinib ... See more keywords
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-019-02075-1
Abstract: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) represents a paradigm shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first-line therapy in clinical practice. While erlotinib, gefitinib… read more here.
Keywords: egfr; treatment; egfr tki; acquired resistance ... See more keywords
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.07.037
Abstract: BACKGROUND Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-rechallenged therapy for EGFR-mutant non-small cell lung cancer (NSCLC) patients who acquired resistance showed moderate efficacy. Considering the high interrelation between EGFR and vascular endothelial growth factor/vascular… read more here.
Keywords: egfr; apatinib; resistance; cell ... See more keywords
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.06.032
Abstract: PURPOSE Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in clinical trials of EGFR-TKI published in 2003-2017, and performed subgroups… read more here.
Keywords: incidence; grade; lung cancer; pneumonitis ... See more keywords
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.07.030
Abstract: PURPOSE Next to secondary epidermal growth factor receptor (EGFR) mutations, cMET amplification plays an important role in mediating acquired resistance to EGFR tyrosine kinase inhibitors (TKI) treatment. Crizotinib, a dual ALK and cMET inhibitor, can… read more here.
Keywords: treatment; cmet amplification; egfr tki; amplification ... See more keywords
Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Sign Up to like & getrecommendations! Published in 2020 at "Pharmacological research"
DOI: 10.1016/j.phrs.2020.105007
Abstract: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were first-line treatments for NSCLC patients with EGFR-mutations. However, about 30 % of responders relapsed within six months because of acquired resistance. In this study, we used Connectivity… read more here.
Keywords: acquired egfr; resistance; lymecycline; cancer ... See more keywords
PPAR&ggr; agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR‐TKI‐resistant lung adenocarcinoma cells via the PPAR&ggr;/PTEN/Akt pathway
Sign Up to like & getrecommendations! Published in 2017 at "Experimental Cell Research"
DOI: 10.1016/j.yexcr.2017.10.024
Abstract: ABSTRACT Development of acquired resistance to EGFR‐TKI therapy continues to be a serious clinical problem in Lung adenocarcinoma management. Peroxisome proliferator‐activated receptor gamma (PPAR&ggr;) agonists demonstrate anti‐tumor activity likely via transactivating genes that regulate cell… read more here.
Keywords: ppar; lung adenocarcinoma; gefitinib; ppar ggr ... See more keywords
Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells
Sign Up to like & getrecommendations! Published in 2022 at "Cell Death Discovery"
DOI: 10.1038/s41420-022-00966-x
Abstract: Activating mutations of epidermal growth factor receptor (EGFR) contributes to the progression of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitor (TKI)-targeted therapy has become the standard treatment for NSCLC patients with EGFR-mutations. However,… read more here.
Keywords: tki; cell; resistance egfr; egfr tki ... See more keywords